{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:36:33Z","timestamp":1789698993030,"version":"4.0.1"},"reference-count":26,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.2967\/jnumed.117.203299","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T19:31:10Z","timestamp":1516303870000},"page":"1219-1224","source":"Crossref","is-referenced-by-count":36,"title":["Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with<sup>89<\/sup>Zr in Human Lymphoma Xenografts"],"prefix":"10.2967","volume":"59","author":[{"given":"Jason T.","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Longtine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette V.","family":"Marquez-Nostra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"2021051712121885000_59.8.1219.1","unstructured":"Cancer stat facts: non-Hodgkin lymphoma. National Cancer Institute Surveillance, Epidemiology, and End Results Program website. http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed April 27, 2018."},{"key":"2021051712121885000_59.8.1219.2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2016.08.001","article-title":"Tumour cell surface antigen targeted therapies in B-cell lymphomas: beyond rituximab","volume":"31","author":"Ku","year":"2017","journal-title":"Blood Rev."},{"key":"2021051712121885000_59.8.1219.3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.33590\/emjoncol\/10314554","article-title":"Rituximab and other new anti-CD20 mabs for non-Hodgkin\u2019s lymphoma treatment","volume":"2","author":"Polito","year":"2014","journal-title":"EMJ Oncol."},{"key":"2021051712121885000_59.8.1219.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"2021051712121885000_59.8.1219.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"2021051712121885000_59.8.1219.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.0892"},{"key":"2021051712121885000_59.8.1219.7","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood."},{"key":"2021051712121885000_59.8.1219.8","unstructured":"Zevalin (ibritumomab tiuxetan) full prescribing information. U.S. Food and Drug Administration website. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125019s210s213lbl.pdf.Revised August 2013. Access April 27, 2018."},{"key":"2021051712121885000_59.8.1219.9","unstructured":"Bexxar (tositumomab and iodine I 131 tositumomab) full prescribing information. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125011s102lbl.pdf. Revised February 2012. Accessed April 27, 2018."},{"key":"2021051712121885000_59.8.1219.10","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3390\/diagnostics7020026","article-title":"Imaging of early response to predict prognosis in the first-line management of follicular non-Hodgkin lymphoma with iodine-131-rituximab radioimmunotherapy","volume":"7","author":"Kesavan","year":"2017","journal-title":"Diagnostics (Basel)."},{"key":"2021051712121885000_59.8.1219.11","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"2021051712121885000_59.8.1219.12","unstructured":"Gazyva (obinutuzumab) full prescribing information. U.S. Food and Drug Administration website. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125486s017s018lbl.pdf. Revised November 2017. Accessed April 27, 2018."},{"key":"2021051712121885000_59.8.1219.13","unstructured":"Arzerra (ofatumumab) full prescribing information. U.S. Food and Drug Administration website. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125326lbl.pdf. Revised October 2009. Accessed April 27, 2018."},{"key":"2021051712121885000_59.8.1219.14","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26333"},{"key":"2021051712121885000_59.8.1219.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0056"},{"key":"2021051712121885000_59.8.1219.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"2021051712121885000_59.8.1219.17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[89Zr]trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol Imaging Biol."},{"key":"2021051712121885000_59.8.1219.18","doi-asserted-by":"publisher","DOI":"10.1021\/mp500323d"},{"key":"2021051712121885000_59.8.1219.19","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"2021051712121885000_59.8.1219.20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00259-016-3560-9","article-title":"Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies","volume":"44","author":"England","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712121885000_59.8.1219.21","doi-asserted-by":"publisher","DOI":"10.1021\/bc300039r"},{"key":"2021051712121885000_59.8.1219.22","first-page":"637","article-title":"Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody","volume":"52","author":"Buchsbaum","year":"1992","journal-title":"Cancer Res."},{"key":"2021051712121885000_59.8.1219.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519623112"},{"key":"2021051712121885000_59.8.1219.24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic Fc engineering: modulation of IgG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol."},{"key":"2021051712121885000_59.8.1219.25","doi-asserted-by":"crossref","first-page":"e0169828","DOI":"10.1371\/journal.pone.0169828","article-title":"Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"12","author":"Jauw","year":"2017","journal-title":"PLoS One."},{"key":"2021051712121885000_59.8.1219.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3025-6"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.117.203299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:09:31Z","timestamp":1693498171000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.117.203299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,2]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.2967\/jnumed.117.203299"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.117.203299","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,18]]}}}